These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16203879

  • 21. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 22. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 23. Ximelagatran.
    Choudhury A, Goyal D, Lip GY.
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [Abstract] [Full Text] [Related]

  • 24. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 25. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 26. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Apr 24; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 27. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 24; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 28. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
    Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT.
    J Bone Joint Surg Am; 2007 Dec 24; 89(12):2648-57. PubMed ID: 18056497
    [Abstract] [Full Text] [Related]

  • 29. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, SPORTIF Executive Steering Committee for the SPORTIF V Investigators.
    JAMA; 2005 Feb 09; 293(6):690-8. PubMed ID: 15701910
    [Abstract] [Full Text] [Related]

  • 30. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec 09; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
    Petersen P, Grind M, Adler J, SPORTIF II Investigators.
    J Am Coll Cardiol; 2003 May 07; 41(9):1445-51. PubMed ID: 12742279
    [Abstract] [Full Text] [Related]

  • 34. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
    Wåhlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, Bylock A, Eriksson BI.
    Thromb Haemost; 2002 Apr 07; 87(4):580-5. PubMed ID: 12008938
    [Abstract] [Full Text] [Related]

  • 35. Summaries for patients. Ximelagatran versus warfarin to prevent blood clots after knee replacement surgery.
    Ann Intern Med; 2002 Oct 15; 137(8):I38. PubMed ID: 12379093
    [No Abstract] [Full Text] [Related]

  • 36. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB, Brookenthal KR, Fitzgerald RH, Williams S, Lonner JH.
    J Bone Joint Surg Am; 2000 Jul 15; 82-A(7):929-38. PubMed ID: 10901307
    [Abstract] [Full Text] [Related]

  • 37. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes.
    Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA.
    Arch Intern Med; 2002 Jul 08; 162(13):1465-71. PubMed ID: 12090882
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H.
    Rev Med Liege; 2003 Dec 08; 58(12):770-3. PubMed ID: 14978854
    [Abstract] [Full Text] [Related]

  • 40. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP.
    Am J Health Syst Pharm; 2005 Jul 15; 62(14):1451-67. PubMed ID: 15998925
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.